Literature DB >> 1645605

Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids.

R Poulin1, D Baker, D Poirier, F Labrie.   

Abstract

This study was designed to assess the multiple steroid receptor mediated activities of a series of synthetic 'progestins' on breast cancer cell growth, using the human ZR-75-1 cell line which possesses functional estrogen (ER), androgen (AR), and glucocorticoid (GR) receptors as well as progesterone (PgR) receptors. Four 17-hydroxyprogesterone derivatives (chlormadinone acetate, CMA; cyproterone acetate, CPA; medroxyprogesterone acetate, MPA; and megestrol acetate, MGA) and two 19-nortestosterone derivatives (norethindrone, NRE, and norgestrel, NRG) were thus investigated. Based on the requirement of estrogens for PgR-mediated antiproliferative effects and the reversal of PgR-mediated action by insulin, it was found that although all 'progestins' could inhibit ZR-75-1 cell growth through the PgR at low concentrations, the relative contribution of this receptor in cell growth control is highly variable between compounds. The quantitative importance of PgR-mediated inhibition of cell proliferation was inversely related to the amplitude of the androgenic effects induced by the compounds, the AR-mediated effects increasing in the order CPA less than MGA less than CMA less than NRE less than NRG less than MPA. The specificity of these androgenic effects is further supported by their reversal upon addition of the antiandrogen hydroxyflutamide. In addition, the 17-hydroxyprogesterone derivatives, but not the 19-nortestosterone derivatives, had glucocorticoid activities at high (micromolar) concentrations, as shown by reversal of growth inhibition by the antagonist RU486 in the presence of saturating concentrations of 5 alpha-dihydro-testosterone. All 'progestins' tested, except MPA and NRE, also had some antiglucocorticoid activity, NRG being the most potent in this respect. Finally, NRE and NRG exerted a marked mitogenic effect in estrogen-free medium which was clearly mediated through the ER as shown by the competitive reversal of their action by the steroidal antiestrogen EM-139. The present results show that growth measurements of the human breast cancer cells ZR-75-1 permit, with the appropriate steroid additions, the assay of progestin, androgen, estrogen, and glucocorticoid agonistic as well as antagonistic activities of test compounds. The present study shows, somewhat surprisingly, that while the AR is almost completely responsible for the action of MPA at low concentrations, the majority of the action of NRE, NRG, and MGA is also exerted through AR, while the androgenic action of CPA plays a lower role in the growth inhibition induced by this compound.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1645605     DOI: 10.1007/bf01806369

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  54 in total

1.  Oral high-dose progestins as treatment for advanced breast cancer.

Authors:  S Lundgren; S Kvinnsland; E Utaaker
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

Review 2.  Metabolism of natural and synthetic steroids used in cancer treatment.

Authors:  A A Sandberg; R Y Kirdani
Journal:  Pharmacol Ther       Date:  1988       Impact factor: 12.310

3.  Apparent positive cooperative effects in cyclic AMP and corticosterone production by isolated adrenal cells in response to ACTH analogues.

Authors:  D Rodbard
Journal:  Endocrinology       Date:  1974-05       Impact factor: 4.736

Review 4.  The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level.

Authors:  F Larrea; F Vilchis; B Chávez; A E Pérez; J Garza-Flores; G Pérez-Palacios
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

Review 5.  The pharmacology and clinical uses of tamoxifen.

Authors:  B J Furr; V C Jordan
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

6.  Estradiol and progesterone receptors content and response to norethisterone treatment in advanced breast cancer.

Authors:  B Clavel; M F Pichon; C Pallud; E Milgrom
Journal:  Eur J Cancer Clin Oncol       Date:  1982-09

7.  Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.

Authors:  R Poulin; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

8.  Progesterone metabolism in T47Dco human breast cancer cells--II. Intracellular metabolic path of progesterone and synthetic progestins.

Authors:  K B Horwitz; A W Pike; C Gonzalez-Aller; P V Fennessey
Journal:  J Steroid Biochem       Date:  1986-12       Impact factor: 4.292

9.  Binding of glucocorticoid antagonists to androgen and glucocorticoid hormone receptors in rat skeletal muscle.

Authors:  P A Danhaive; G G Rousseau
Journal:  J Steroid Biochem       Date:  1986-02       Impact factor: 4.292

10.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

View more
  12 in total

Review 1.  KISS1 in breast cancer progression and autophagy.

Authors:  Ilya V Ulasov; Anton V Borovjagin; Peter Timashev; Massimo Cristofanili; Danny R Welch
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

2.  Progesterone induces progesterone receptor gene (PGR) expression via rapid activation of protein kinase pathways required for cooperative estrogen receptor alpha (ER) and progesterone receptor (PR) genomic action at ER/PR target genes.

Authors:  Caroline H Diep; Hannah Ahrendt; Carol A Lange
Journal:  Steroids       Date:  2016-09-15       Impact factor: 2.668

Review 3.  Postmenopausal hormone therapy: an Endocrine Society scientific statement.

Authors:  Richard J Santen; D Craig Allred; Stacy P Ardoin; David F Archer; Norman Boyd; Glenn D Braunstein; Henry G Burger; Graham A Colditz; Susan R Davis; Marco Gambacciani; Barbara A Gower; Victor W Henderson; Wael N Jarjour; Richard H Karas; Michael Kleerekoper; Roger A Lobo; JoAnn E Manson; Jo Marsden; Kathryn A Martin; Lisa Martin; JoAnn V Pinkerton; David R Rubinow; Helena Teede; Diane M Thiboutot; Wulf H Utian
Journal:  J Clin Endocrinol Metab       Date:  2010-06-21       Impact factor: 5.958

Review 4.  Role of the androgen receptor in human breast cancer.

Authors:  S N Birrell; R E Hall; W D Tilley
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

5.  Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice.

Authors:  Till Freudenberger; Marc Oppermann; Andrea Marzoll; Hans-Karl Heim; Peter Mayer; Georg Kojda; Artur A Weber; Karsten Schrör; Jens W Fischer
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

6.  Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor.

Authors:  R Hackenberg; T Hawighorst; A Filmer; A H Nia; K D Schulz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

7.  Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate.

Authors:  S Li; M Lepage; Y Mérand; A Bélanger; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

8.  Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly.

Authors:  S-S Yeh; S Lovitt; M W Schuster
Journal:  J Nutr Health Aging       Date:  2009-05       Impact factor: 4.075

9.  Controlled release low dose medroxyprogesterone acetate (MPA) inhibits the development of mammary tumors induced by dimethyl-benz(a) anthracene in the rat.

Authors:  F Labrie; S Li; A Bélanger; J Côté; Y Mérand; M Lepage
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

10.  Inhibitory effect of a steroidal antiestrogen (EM-170) on estrone-stimulated growth of 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.

Authors:  F Labrie; S Li; C Labrie; C Lévesque; Y Mérand
Journal:  Breast Cancer Res Treat       Date:  1995-03       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.